Second line of treatment for HER2-positive gastric cancer: an evolving issue

Rep Pract Oncol Radiother. 2021 Apr 14;26(2):316-317. doi: 10.5603/RPOR.a2021.0024. eCollection 2021.

¹ Department of Health Sciences, University of Florence, Florence, Italy.
² Department of Biology and Biochemistry, University of Bath, Bath, England, United Kingdom.

No abstract available

Keywords: gastric cancer; paclitaxel; ramucirumab; second line; trastuzumab.